Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 4Uterine Cervical Dysplasia 3Papilloma 1Neoplasms, Squamous Cell 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Neoplasms 1

Interventions

napabucasin 2Irinotecan 2Gemcitabine 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2sipuleucel-T 1pralsetinib 1pembrolizumab 1luprolide acetate gel depot 1catumaxomab 1Vaccines 1Papillomavirus Vaccines 1Papanicolaou Test 1Leuprolide 1Leucovorin 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Human Papillomavirus DNA Tests 1Fluorouracil 1Colposcopy 1Cisplatin 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Glandular and Epithelial × Colposcopy × Clear all
NCT01234480 2023-05-16

Intended Use Study of the BD SurePath Plusâ„¢ Pap

Becton, Dickinson and Company

Terminated
5,859 enrolled 4 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡